8-K

0001683168-24-002761.txt : 20240429 0001683168-24-002761.hdr.sgml : 20240429 20240429080033 ACCESSION NUMBER: 0001683168-24-002761 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240426 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240429 DATE AS OF CHANGE: 20240429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mosaic ImmunoEngineering Inc. CENTRAL INDEX KEY: 0000836564 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841070278 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22182 FILM NUMBER: 24886655 BUSINESS ADDRESS: STREET 1: 9114 ADAMS AVE. STREET 2: #202 CITY: HUNTINGTON BEACH STATE: CA ZIP: 92646 BUSINESS PHONE: 657-208-0890 MAIL ADDRESS: STREET 1: 9114 ADAMS AVE. STREET 2: #202 CITY: HUNTINGTON BEACH STATE: CA ZIP: 92646 FORMER COMPANY: FORMER CONFORMED NAME: PATRIOT SCIENTIFIC CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: PATRIOT FINANCIAL CORP DATE OF NAME CHANGE: 19920521 8-K 1 mosaic_8k.htm CURRENT REPORT 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 26, 2024

MOSAIC IMMUNOENGINEERING, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-22182

84-1070278

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

9114 Adams Ave., #202

Huntington Beach, California 94646

(Address of principal executive offices, and zip code)

Registrant’s telephone number, including area code: (657) 208-0890

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD

On April 29, 2024, the Company issued a press release announcing the Agreement. A copy of the press release is furnished as Exhibit 99.1 hereto, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 8.01

Other Events

On April 26, 2024, Mosaic ImmunoEngineering, Inc. a Delaware corporation (the “Company” or “Mosaic”), entered into a binding term sheet (the “Binding Term Sheet”) with Oncotelic Therapeutics, Inc. (“Oncotelic”) whereby the Company intends to acquire certain rights to technologies from Oncotelic, including its clinical stage necroptosis cancer therapies associated with Oncotelic’s vascular disruptive agents (“VDAs”) and related regulatory and clinical packages. The Company will also have access to Oncotelic’s proprietary Artificial Intelligence (“AI”) technologies for identifying immunotherapy combinations. In exchange for the rights to these technologies, the Company would issue Oncotelic shares of its common stock valued at $15.0 million upon execution of the definitive agreement, or a combination common stock and preferred stock to be determined by the parties, along with additional milestones allowing Oncotelic to earn up to an additional $15.0 million in shares of common stock that would be valued at the time of issuance, if earned.

In addition, under the Binding Term Sheet, (i) Mosiac would continue the development work necessary to achieve the mutually agreed upon milestones upon the requisite funding, (ii) Oncotelic will provide a loan to Mosaic to cover certain operational costs of the Company through June 1, 2024, (iii) Oncotelic will assist the Company in potentially raising initial funding to support the technologies of $2 million, and (iv) in the event the Company is unable to raise the requisite funding, then the transaction may proceed to a reverse acquisition/merger, with conditions typical of such a transaction.

Pursuant to the Binding Term Sheet, the parties agreed to negotiate in good faith towards the execution of the Definitive Agreements and the closing of the transactions contemplated thereby, which will be subject to customary due diligence and other conditions as described in the Binding Term Sheet.

The foregoing summary of the Binding Term Sheet does not purport to be complete and is subject to, and qualified in its entirety by, such document attached as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit No.		Description
10.1		Binding Term Sheet dated April 26, 2024
99.1		Press Release issued by Mosaic ImmunoEngineering, Inc. on April 29, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Mosaic ImmunoEngineering, Inc.



Date: April 29, 2024		By: /s/ Steven King
		Steven King
		President and Chief Executive Officer, Director

2

EX-10.1 2 mosaic_ex1001.htm BINDING TERM SHEET DATED APRIL 26, 2024

Exhibit 10.1

CONFIDENTIAL

April 26, 2024

Oncotelic Therapeutics, Inc.

Vuong Trieu

29397 Agoura Rd, Suite 107

Agoura Hills, CA 91301

Dear Vuong:

This letter, together with the attached binding term sheet attached hereto, sets forth our mutual understanding regarding a possible commercial relationship referred to as the “Transaction” between Mosaic ImmunoEngineering, Inc., a Delaware corporation (“Mosaic”) and Oncotelic Therapeutics, Inc., a Delaware corporation (“Oncotelic”). It is understood that any such transaction is subject to our mutual agreement on terms through a definitive document entered into by Mosaic and Oncotelic formalizing the Transaction.

1.Terms. Attached as Exhibit A to this letter is a summary of the terms of the Transaction (“Term Sheet”). The Term Sheet does not purport to include all conditions, covenants, representations, warranties and other terms that would be contained in definitive documents for the Transaction. However, this letter confirms each parties agreement to use commercially reasonable efforts to negotiate and enter into definitive agreements for the Transaction in accordance with the terms set forth on the Term Sheet.

2.Due Diligence. Subject to execution of mutually satisfactory confidentiality agreements, Mosaic and Oncotelic each agree to provide representatives of other, and its accounting, legal and other advisers, with reasonable access to the information that such party reasonably requests for purposes of evaluating the Transaction. Each party shall commence due diligence upon the signing of this letter and complete such due diligence within 30 days of the signing of this letter. Each party shall cause its employees, officers, directors, consultants, representatives, advisors and agents to, cooperate with the other party in its due diligence review.

3.Miscellaneous. This letter may be signed in counterparts, all of which shall constitute the same agreement, and shall be governed by the substantive laws of California. This offer, unless accepted, will expire at 5:00 p.m. Pacific time, on May 1, 2024.

If the foregoing is in accordance with your understanding, please sign this letter in the space indicated below.

Very truly yours,

MOSAIC IMMUNOENGINEERING, INC.

/s/ Steven King

Steven King

President and CEO

9114 Adams Avenue, #202, Huntington Beach, CA 94646

www.mosaicie.com | info@mosaicie.com

The foregoing is hereby
Agreed to and accepted:

ONCOTELIC THERAPEUTICS, INC.

By /s/ Vuong Trieu

Its CEO

Date 4/26/2024

2

EXHIBIT A

TERMS FOR THE TRANSACTION

Effective Date		April 26, 2024

Transaction:		Mosaic will acquire from Oncotelic certain assets and technologies described below (the “Oncotelic Technologies”) in exchange for equity interests in Mosaic as part of a transaction (the “Transaction”). The parties will explore the most tax advantageous structure for the Transaction.

Acquisition of Oncotelic Technologies:		Mosaic will acquire the Oncotelic Technologies in exchange for 47,923,322 unregistered shares of common stock of Mosaic (the “Consideration”) valued at $15.0 million based on a price of $0.313 being the closing share price of Mosaic’s common stock on the date that is one day prior to the Effective Date. If necessary to complete the Transaction, Mosaic shall issue Oncotelic shares of convertible preferred stock for a portion of the Consideration. The rights, privileges and preferences for the preferred stock shall be defined in the definitive agreement, if applicable. In addition, Mosaic shall pay to Oncotelic additional Consideration in the form of an earn out based on achievement of mutually acceptable milestones to be achieved within 4 years (i.e. licensing transaction(s) resulting in at least an additional $15.0 million in aggregate cash proceeds received by the Company) to be agreed and reflected in the definitive agreements for the transaction. The amount of the earnout Consideration shall be up to $15.0 million which shall be payable in additional shares of common stock of Mosaic valued at the time of issuance.

Oncotelic Technologies		The Oncotelic Technologies to be transferred include components related to Necroptosis Cancer including: 1) a license to CA4P for direct intratumoral administration, all veterinary applications and all ocular disease applications including all regulatory, CMC, clinical and nonclinical data packages submitted to any regulatory authorities including but not limited to the FDA, EMA, Health Canada and the MHRA for CA4P; and 2) non-exclusive access to AI technologies and IP for the development of CA4P for these indications including biomarker and patient selection.

Development Activities:		Mosaic will continue the development work necessary to achieve the mutually agreed upon milestones which will include an annual budget of $2.0 – $2.5 million. The specifics of the budget will be mutually agreed upon between Mosaic and Oncotelic.

Representations and Warranties:		The definitive agreements for the Transaction will contain representations, warranties and covenants of Oncotelic and Mosaic customary for transactions of this nature.

Fees and Expenses:		The respective fees and expenses including financial adviser, broker, legal, accounting and other fees shall be included in the annual budget.

A-1

Other Covenants:		1)	Oncotelic will advance to Mosaic the mutually agreed upon cost of Mosaic’s annual audit and operational costs of Mosaic until June 1st, 2024. Payments will be made following receipt of invoices. Such payments shall be treated as a loan, and shall be repaid in cash upon the closing of a financing raising at least $2.0 million or repaid with additional shares of common stock of Mosaic (valued at the time of such issuance), as requested by Oncotelic.

		2)	Mosaic will use commercially reasonable efforts to seek to raise $2.0 million in an equity financing to fund its annual budget and operating costs. Oncotelic will cooperate with Mosaic in its financing efforts, including attending meetings and providing technical support related to the Oncotelic Technologies.

		3)	In the event that Mosaic is unable to secure an equity financing in an amount sufficient to support ongoing operations, the transaction will proceed as a reverse merger of an Oncotelic subsidiary into Mosaic, as well as the transition of management, board of directors and assumption of Mosaic’s liabilities as is typical in a reverse merger. Mosaic will use reasonable best efforts within its control to convert existing liabilities of Mosaic into shares of common stock of Mosaic, provided such conversion has no tax consequences to liability holders.

Expiration and Conditions:	This Term Sheet shall be considered binding and shall expire on the earlier of (1) the execution and delivery of mutually acceptable definitive agreements for the Transaction or (2) 90 days from the Effective Date. In addition, the execution of definitive agreements and the consummation of the Transaction on the terms set forth in the Term Sheet is subject to the following conditions:

		·	Each party’s satisfaction with its due diligence review of the other party’s business and operations.

		·	The negotiation of mutually acceptable definitive agreements for the Transaction.

		·	The approval of each party’s shareholders to the extent required by applicable corporate law or securities regulation, including the rules of any applicable stock exchange.

		·	Mosaic receiving waivers from at least 90% of its convertible note holders under Section 4 of the Convertible Note Purchase Agreement, whereby holders would agree to waive any payment due in cash due upon a “Corporate Transaction”, as defined therein.

	Either party may terminate this Term Sheet upon failure of one or more of the forgoing conditions.

A-2

EX-99.1 3 mosaic_ex9901.htm PRESS RELEASE

Exhibit 99.1

Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.

—The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic’s AI platform for identifying immunotherapy combinations —

Huntington Beach, Calif., April 29, 2024 – Mosaic ImmunoEngineering, Inc. (“Mosaic” or the “Company”), (OTCPK: CPMV), a development-stage biotechnology company focused on the development of novel immunotherapies to treat and prevent cancer, today announced the signing of a binding term-sheet with Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”), under which Mosaic intends to acquire rights to certain of Oncotelic’s clinical stage necroptosis cancer therapies associated with Oncotelic’s vascular disruptive agents (“VDAs”). Oncotelic’s VDA necroptosis therapeutics are expected to work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death receptor” activation, which can result in a robust anti-cancer immune response. In addition to the clinical stage assets, Mosaic will have non-exclusive access to Oncotelic’s proprietary AI technologies for identifying immunotherapy combinations.

Pursuant to the term-sheet, Mosaic will issue Oncotelic shares of its common stock valued at $15.0 million upon execution of the definitive agreement, or a combination common stock and preferred stock to be determined by the parties, along with additional milestones allowing Oncotelic to earn up to an additional $15.0 million in shares of common stock valued at the time of issuance, if earned. The Mosaic team, which has broad experience in bringing oncology and orphan drug products to market with combined experience with well over 30 FDA and worldwide product approvals, will be responsible for advancing the development of the technologies. Oncotelic and Mosaic will work closely to ensure a smooth transfer of the technologies from Oncotelic to Mosaic. Oncotelic will provide short-term financial support for the program while the teams work together to achieve both short-term and long-term financing goals.

The binding term sheet is subject to customary due diligence requirements and other conditions, including but not limited to, obtaining appropriate shareholder approval for the transaction.

"We are very pleased to have this opportunity to bring clinical stage assets into the company as we look to build a pipeline of oncology products with the potential to treat multiple types of cancer. In particular, the necroptosis agents we are acquiring have promise in areas with high unmet medical need such as uveal melanoma and retinoblastoma. We look forward to working with the Oncotelic team to complete the transaction and to initiating the technology transfer process so that we can advance the program into new clinical trials." said Steven King, President and CEO of Mosaic.

“We are delighted to announce our collaboration with the distinguished team at Mosaic to advance our AI-driven necroptosis cancer therapies. Mosaic is well-equipped to rapidly develop and refine this groundbreaking technology. Together, we expect to deliver significant advancements in the field of oncology with this technology.” expressed Dr. Vuong Trieu, CEO of Oncotelic.

1

About Necroptosis Cancer Therapies

A recent approval of tumor infiltrating lymphocyte, or TIL cell therapy demonstrates how to manipulate patient immunity against cancer for lasting cure. However, TIL cell therapy is costly, time consuming and technologically challenging. Instead of driving TIL cells externally, Necroptosis Cancer Therapies drive innate TILs to the tumor. The key step is the induction of necrotic cell death and activation of death genes, exposing tumor-reactive antigens to initiate an immune response, activating antigen-presenting cells (APCs) to achieve large-scale antigen presentation, activating T-cells, inducing strong and sustained cytotoxic T lymphocyte responses, and ultimately triggering a TIL antitumor immune effect. Necroptosis Cancer Therapies can use Vascular Disrupting Agents (VDAs) in combination with Check-Point Inhibitors (CKIs) and other Immuno-Oncology (IO) agents to drive TIL cells to the tumor. Our VDAs can act as a component for the TIL/Necroptosis Cancer Therapies. The Necroptosis Cancer Therapies will be developed in conjunction with Artificial Intelligence (AI) technology using a list of proprietary death genes.

About Mosaic ImmunoEngineering, Inc.

Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing cancer therapies for areas of high unmet medical need. Mosaic’s management and board of directors’ team has broad experience in bringing oncology and orphan drug products to the market with a combined experience including well over 30 FDA and worldwide product approvals. For additional information about Mosaic, please visit www.MosaicIE.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss Mosaic’s future operations and its ability to successfully advance the product candidates; the nature, strategy and focus of Mosaic’s business; and the development and commercial potential and potential benefits of any of Mosaic’s product candidates. Mosaic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Mosaic’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of these forward-looking statements could differ materially from those described in or implied by the statements in this press release, including the uncertainties of: entering into a definitive agreement with Oncotelic, obtaining shareholder approval for the transaction with Oncotelic, successfully completing due diligence under the binding term sheet, raising sufficient capital or grant funding to advance the underlying product candidates under the binding term sheet, which may not be available on favorable terms or at all; advancing the VDA technology into clinical trials, the clinical development and regulatory approval of product candidates under the binding term sheet, including potential delays in the commencement; enrollment and completion of clinical trials; risks related to business interruptions, including but not limited to, the outbreak of new variants of COVID-19 coronavirus, which could harm Mosaic’s financial condition and increase its costs and expenses. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risks discussed in Mosaic's filings with the Securities and Exchange Commission. Except as otherwise required by law, Mosaic disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether, as a result of new information, future events or circumstances or otherwise.

Contact: Jay Carlson

Sr. Manager, Investor Relations

Mosaic ImmunoEngineering, Inc.

info@mosaicie.com

Strategic corporate inquiries can be sent to partnering@mosaicie.com

2

EX-101.SCH 4 cpmv-20240426.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 cpmv-20240426_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 cpmv-20240426_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 image001.jpg GRAPHIC begin 644 image001.jpg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image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 26, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 26, 2024
Entity File Number	0-22182
Entity Registrant Name	MOSAIC IMMUNOENGINEERING, INC.
Entity Central Index Key	0000836564
Entity Tax Identification Number	84-1070278
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9114 Adams Ave.
Entity Address, City or Town	Huntington Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94646
City Area Code	(657)
Local Phone Number	208-0890
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 19 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mosaicie.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cpmv-20240426.xsd cpmv-20240426_lab.xml cpmv-20240426_pre.xml mosaic_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mosaic_8k.htm": { "nsprefix": "CPMV", "nsuri": "http://mosaicie.com/20240426", "dts": { "schema": { "local": [ "cpmv-20240426.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "cpmv-20240426_lab.xml" ] }, "presentationLink": { "local": [ "cpmv-20240426_pre.xml" ] }, "inline": { "local": [ "mosaic_8k.htm" ] } }, "keyStandard": 19, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 19 }, "report": { "R1": { "role": "http://mosaicie.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "mosaic_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "mosaic_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://mosaicie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001683168-24-002761-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-002761-xbrl.zip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

XML 20 mosaic_8k_htm.xml IDEA: XBRL DOCUMENT 0000836564 2024-04-26 2024-04-26 iso4217:USD shares iso4217:USD shares false 0000836564 8-K 2024-04-26 MOSAIC IMMUNOENGINEERING, INC. DE 0-22182 84-1070278 9114 Adams Ave. Huntington Beach CA 94646 (657) 208-0890 false false false false false